Evidence map›Paper›PMID 34626358›Full record

ReviewCancer treatment and research2021

Current Management and New Developments in the Treatment of Myelodysplastic Syndrome.

Shukaib Arslan, Samer Khaled, Ryotaro Nakamura

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer treatment and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Shukaib ArslanCity of Hope National Medical Center, 1500 E Duarte Rd., Duarte, CA, 91010, USA.
Samer KhaledCity of Hope National Medical Center, 1500 E Duarte Rd., Duarte, CA, 91010, USA.
Ryotaro NakamuraCity of Hope National Medical Center, 1500 E Duarte Rd., Duarte, CA, 91010, USA. rnakamura@coh.org.
City Of Hope National Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myelodysplastic syndrome (MDS) is a heterogeneous hematological neoplasm with a wide range of clinical presentations from isolated anemia to pancytopenia and propensity to transform to acute myeloid leukemia. MDS is characterized by morphologic bone marrow dysplasia and ineffective hematopoiesis resulting from a range of cytogenetic abnormalities and somatic gene mutations. Disease management varies from observation alone for low-risk disease to hypomethylating agents and hematopoietic cell transplantation (HCT) for higher risk disease. In this chapter, we review the classification, risk stratification, and optimal management of patients with MDS.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMyelodysplastic SyndromesChromosome AberrationsHumans2 (MDS-EB15q- syndromeAllogeneic hematopoietic cell transplant (alloHCT)EB2)Hypomethylating agentsMyelodysplastic syndrome (MDS)Myelodysplastic syndrome with excess blast 1

Identifiers

PMID34626358
OpenAlexW3203303294

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.